Compare Stocks: MNKD, EWTX, ACAD, and PBLS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$27.29 -0.6%	$27.64	$19.69 ▼ $30.96	$4.73B	0.86	1.26 million shs	5.48 million shs
EWTX Edgewise Therapeutics	$45.32 -3.5%	$42.61	$14.09 ▼ $48.51	$5.10B	0.32	1.16 million shs	1.99 million shs
MNKD MannKind	$3.54 -1.1%	$3.95	$2.23 ▼ $6.51	$1.15B	1.1	2.77 million shs	5.51 million shs
PBLS Parabilis Medicines	$41.73 +2.1%	$35.93	$24.51 ▼ $42.49	$5.05B	N/A	471,980 shs	9.09 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	-0.58%	-1.94%	-9.67%	+26.23%	+12.77%
EWTX Edgewise Therapeutics	-3.45%	+2.07%	-2.41%	+22.91%	+226.28%
MNKD MannKind	-1.12%	-5.60%	-19.36%	-10.15%	-34.32%
PBLS Parabilis Medicines	+2.08%	+13.15%	+0.99%	+61.43%	+4,172,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$27.29 -0.6%	$27.64	$19.69 ▼ $30.96	$4.73B	0.86	1.26 million shs	5.48 million shs
EWTX Edgewise Therapeutics	$45.32 -3.5%	$42.61	$14.09 ▼ $48.51	$5.10B	0.32	1.16 million shs	1.99 million shs
MNKD MannKind	$3.54 -1.1%	$3.95	$2.23 ▼ $6.51	$1.15B	1.1	2.77 million shs	5.51 million shs
PBLS Parabilis Medicines	$41.73 +2.1%	$35.93	$24.51 ▼ $42.49	$5.05B	N/A	471,980 shs	9.09 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	-0.58%	-1.94%	-9.67%	+26.23%	+12.77%
EWTX Edgewise Therapeutics	-3.45%	+2.07%	-2.41%	+22.91%	+226.28%
MNKD MannKind	-1.12%	-5.60%	-19.36%	-10.15%	-34.32%
PBLS Parabilis Medicines	+2.08%	+13.15%	+0.99%	+61.43%	+4,172,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.78	Moderate Buy	$34.36	25.91% Upside
EWTX Edgewise Therapeutics	2.82	Moderate Buy	$50.33	11.06% Upside
MNKD MannKind	2.50	Moderate Buy	$8.34	135.70% Upside
PBLS Parabilis Medicines	2.71	Moderate Buy	$41.67	-0.15% Downside

Current Analyst Ratings Breakdown

Latest MNKD, EWTX, ACAD, and PBLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2026	MNKD MannKind	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$8.00
9/4/2026	PBLS Parabilis Medicines	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D)
9/3/2026	MNKD MannKind	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/25/2026	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
8/25/2026	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$27.00 ➝ $28.00
8/25/2026	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$39.00 ➝ $40.00
8/20/2026	EWTX Edgewise Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$53.00 ➝ $60.00
8/17/2026	ACAD ACADIA Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $49.00
8/12/2026	ACAD ACADIA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/12/2026	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$38.00 ➝ $41.00
8/11/2026	EWTX Edgewise Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$32.00 ➝ $36.00

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$1.07B	4.39	$0.88 per share	30.94	$7.25 per share	3.76
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.93 per share	N/A
MNKD MannKind	$393.63M	2.89	$0.06 per share	57.85	($0.17) per share	-20.82
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$391M	$2.22	12.29	27.85	N/A	33.42%	9.03%	6.79%	11/4/2026 (Estimated)
EWTX Edgewise Therapeutics	-$167.79M	-$1.85	N/A	N/A	N/A	N/A	-39.01%	-36.96%	11/5/2026 (Estimated)
MNKD MannKind	$5.86M	-$0.13	N/A	N/A	N/A	-11.08%	-11.21%	-6.31%	11/4/2026 (Estimated)
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest MNKD, EWTX, ACAD, and PBLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	PBLS Parabilis Medicines	-$0.16	-$2.32	-$2.16	-$2.32	N/A	$0.15 million
8/6/2026	Q2 2026	EWTX Edgewise Therapeutics	-$0.4677	-$0.53	-$0.0623	-$0.53	N/A	N/A
8/5/2026	Q2 2026	MNKD MannKind	-$0.0075	-$0.01	-$0.0025	-$0.06	$108.08 million	$109.37 million
8/4/2026	Q2 2026	ACAD ACADIA Pharmaceuticals	$0.0682	$0.18	+$0.1119	$0.18	$296.55 million	$308.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	N/A	N/A	N/A	N/A	N/A
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	3.39	3.30
EWTX Edgewise Therapeutics	N/A	16.24	16.24
MNKD MannKind	N/A	1.72	1.41
PBLS Parabilis Medicines	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
EWTX Edgewise Therapeutics	N/A
MNKD MannKind	49.55%
PBLS Parabilis Medicines	N/A

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.20%
EWTX Edgewise Therapeutics	21.30%
MNKD MannKind	2.60%
PBLS Parabilis Medicines	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	798	172.31 million	127.16 million	Optionable
EWTX Edgewise Therapeutics	127	108.60 million	85.47 million	Optionable
MNKD MannKind	592	321.54 million	313.18 million	Optionable
PBLS Parabilis Medicines	145	123.53 million	N/A	N/A

MNKD, EWTX, ACAD, and PBLS Headlines

Recent News About These Companies

Why Parabilis Medicines, Inc.’s (PBLS) Stock Is Up 10.09%

September 17 at 12:07 AM | aaii.comA

Parabilis Medicines (NASDAQ:PBLS) Hits New 52-Week High - Time to Buy?

September 17 at 12:59 PM | marketbeat.com

48,484 Shares in Parabilis Medicines, Inc. $PBLS Acquired by Squarepoint Ops LLC

September 17 at 3:43 AM | marketbeat.com

Parabilis Medicines, Inc. (PBLS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 16 at 10:39 PM | seekingalpha.com

Parabilis Medicines (NASDAQ:PBLS) Trading Up 6% - Still a Buy?

September 16 at 11:59 AM | marketbeat.com

WINTON GROUP Ltd Takes Position in Parabilis Medicines, Inc. $PBLS

September 14, 2026 | marketbeat.com

Parabilis Medicines Inc PBLS

September 10, 2026 | morningstar.comM

Why Parabilis Medicines, Inc.’s (PBLS) Stock Is Down 5.03%

September 10, 2026 | aaii.comA

1,920,805 Shares in Parabilis Medicines, Inc. $PBLS Purchased by Frazier Life Sciences Management L.P.

September 7, 2026 | marketbeat.com

Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

September 1, 2026 | globenewswire.com

ICONIQ Capital LLC Takes $9.58 Million Position in Parabilis Medicines, Inc. $PBLS

August 31, 2026 | marketbeat.com

Regeneron Pharmaceuticals Inc. Buys New Stake in Parabilis Medicines, Inc. $PBLS

August 29, 2026 | marketbeat.com

1,600,937 Shares in Parabilis Medicines, Inc. $PBLS Purchased by General Catalyst Group Management LLC

August 28, 2026 | marketbeat.com

venBio Partners LLC Purchases Shares of 5,266,697 Parabilis Medicines, Inc. $PBLS

August 28, 2026 | marketbeat.com

Jupiter Topco LLC Buys Shares of 2,296,547 Parabilis Medicines, Inc. $PBLS

August 28, 2026 | marketbeat.com

Parabilis Medicines, Inc. (NASDAQ:PBLS) Given Consensus Rating of "Buy" by Analysts

August 26, 2026 | marketbeat.com

ARCH Venture Management LLC Makes New $175.52 Billion Investment in Parabilis Medicines, Inc. $PBLS

August 26, 2026 | marketbeat.com

Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors

August 25, 2026 | markets.businessinsider.com

Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D.

August 25, 2026 | globenewswire.com

ICONIQ Capital LLC Makes New Investment in Parabilis Medicines, Inc. $PBLS

August 24, 2026 | marketbeat.com

Éléments financiers clés - PBLS

August 23, 2026 | fr.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNKD, EWTX, ACAD, and PBLS Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$27.29 -0.16 (-0.58%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$27.22 -0.07 (-0.26%)

As of 09/18/2026 07:55 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Edgewise Therapeutics NASDAQ:EWTX

$45.32 -1.62 (-3.45%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$44.85 -0.47 (-1.04%)

As of 09/18/2026 07:30 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

MannKind NASDAQ:MNKD

$3.54 -0.04 (-1.12%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.59 +0.05 (+1.36%)

As of 09/18/2026 07:59 PM Eastern

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Parabilis Medicines NASDAQ:PBLS

$41.73 +0.85 (+2.08%)

As of 09/18/2026 04:00 PM Eastern

Parabilis Medicines Inc. is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc. is based in CAMBRIDGE, Mass.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MNKD, EWTX, ACAD, and PBLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MNKD, EWTX, ACAD, and PBLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MNKD, EWTX, ACAD, and PBLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNKD, EWTX, ACAD, and PBLS Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

Edgewise Therapeutics NASDAQ:EWTX

MannKind NASDAQ:MNKD

Parabilis Medicines NASDAQ:PBLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MNKD, EWTX, ACAD, and PBLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MNKD, EWTX, ACAD, and PBLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MNKD, EWTX, ACAD, and PBLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNKD, EWTX, ACAD, and PBLS Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

Edgewise Therapeutics NASDAQ:EWTX

MannKind NASDAQ:MNKD

Parabilis Medicines NASDAQ:PBLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools